Effect of Moderate Red Wine versus Vodka Consumption on Inflammatory Markers Related to Cardiovascular Disease Risk: A Randomized Crossover Study

Amy Wotherspoon, Sarah Elshahat, Nicholas McAlinden, Katrina Dean, Ian S. Young, Peter C. Sharpe, Stefan Blankenburg, Chris C. Patterson, Michelle C. McKinley, Alun Evans & Jayne V. Woodside

To cite this article: Amy Wotherspoon, Sarah Elshahat, Nicholas McAlinden, Katrina Dean, Ian S. Young, Peter C. Sharpe, Stefan Blankenburg, Chris C. Patterson, Michelle C. McKinley, Alun Evans & Jayne V. Woodside (2019): Effect of Moderate Red Wine versus Vodka Consumption on Inflammatory Markers Related to Cardiovascular Disease Risk: A Randomized Crossover Study, Journal of the American College of Nutrition, DOI: 10.1080/07315724.2019.1695234

To link to this article: https://doi.org/10.1080/07315724.2019.1695234

Published online: 26 Nov 2019.
Effect of Moderate Red Wine versus Vodka Consumption on Inflammatory Markers Related to Cardiovascular Disease Risk: A Randomized Crossover Study


*Centre for Public Health, Queen’s University Belfast, Institute of Clinical Sciences B, Belfast, UK; **Clinical Biochemistry, Craigavon Area Hospital, Craigavon, UK; †University Heart Centre Hamburg, Hamburg, Germany

ABSTRACT

Objective: Few interventions have tested the effects of different alcohol types on cardiovascular risk biomarkers. The aim of this study was to investigate the effects of red wine versus vodka on inflammatory and vascular health-related biomarkers.

Methods: In a crossover study, participants were randomized to receive either red wine or vodka (3 units/day) for 2 weeks. Following a 2-week washout period, participants then consumed the alternate alcoholic drink for 2 weeks. Fasting blood samples were collected just prior to and at the end of each 2-week period. A total of 13 inflammatory and vascular health biomarkers were assessed.

Results: A total of 77 of 85 recruited healthy men completed the study. Leptin levels were significantly raised after each intervention (p < 0.01). APO A1 significantly increased following vodka, but not red wine, intervention (p ≤ 0.01). A significant difference between the interventions was noted for adiponectin only (p < 0.01), although neither of the within-group changes were statistically significant (p > 0.01).

Conclusions: The current study found significantly increased levels of leptin following both red wine and vodka consumption, increased levels of APO A1 following vodka consumption, and significant difference between both interventions for adiponectin only. Further studies are needed to investigate the effects of longer-term alcohol consumption on inflammatory and vascular health biomarkers.

Introduction

Epidemiological evidence has suggested that moderate alcohol consumption plays a protective role against cardiovascular disease (CVD) among general populations (1, 2). It was also shown to significantly reduce the incidence of premature mortality among CVD patients (3). The nature of this relationship appears to be J-shaped, with abstainers and heavy alcohol drinkers having greater cardiovascular mortality than moderate drinkers (4). A recent viewpoint by Costanzo et al. (5), however, showed continuing scientific debate over the J-shaped relationship between alcohol intake and mortality. While some studies showed evidence of no protective effect of moderate alcohol on cardiovascular outcomes (6, 7), others demonstrated significant protective effects (1, 2). Costanzo et al. (5) revealed that these conflicting results may be explained by potential confounders and selection bias (e.g. failure to correctly classify exposure-heavy versus moderate drinkers- due to self-reporting issues) in different epidemiological studies.

Observational studies have suggested a reduction in inflammatory markers, such as C-reactive protein (CRP) (8), and an increase in anti-inflammatory modulators, such as adiponectin (1), in moderate alcohol drinkers compared with abstainers. The protective cardiovascular effects of alcohol may therefore be mediated through anti-inflammatory, or other vascular health-promoting mechanisms. Whilst likely mechanisms have been postulated for this possible protective effect, the exact mechanisms by which alcohol exerts protective effects are also yet to be elucidated (4), but may relate to type of alcohol consumed.

Red wine has been of particular interest in relation to cardiovascular protective effects (9). Evidence for other alcoholic beverages also indicates some benefit, but to a lesser extent than for red wine (10, 11). In a meta-analysis of beer and wine studies, the vascular risk significantly decreased by 32 and 22% in wine and beer drinkers relative to non-drinkers, respectively (10). In addition to the alcohol content, red wine contains a number of other compounds including polyphenols, which may mediate cardiovascular protection via other mechanisms, yet their subtherapeutic concentrations in red wine pose a limitation to clinical trials (12). Polyphenols may act by scavenging free radicals, reducing vascular tone and suppressing inflammatory mechanism.
which facilitate the development of CVD (12). There is limited research, on the other hand, investigating the effect of vodka on cardio-vascular health. A randomized controlled 28-day vodka (30 g/day) trial by Joosten et al. (13) demonstrated some cardioprotective effects through significantly reducing interleukin-18 (IL-18) levels.

Given the lack of alcohol intervention studies in general, and specific testing of different alcoholic beverages, the current study aimed at assessing the effect of short-term moderate alcohol consumption on a panel of inflammatory and other vascular health markers. This study also aimed to determine whether the effects of intervention differed depending on type of alcohol consumed (red wine or vodka). Part of this study has already been published with respect to assessing total homocysteine (tHcy), folate, and vitamin B12 concentrations, where the 14-day alcohol intervention significantly decreased folate and vitamin B12 levels, and significantly raised plasma tHcy concentrations (14).

**Patients and methods**

**Study design**

This randomized, crossover study included recruitment of 85 healthy male subjects aged 21-70 years from hospital workforce and the general population. Exclusion criteria included consumption of >21 units alcohol/week, detection of abnormal liver function, taking any vitamin and mineral supplements and any serious concurrent health conditions (e.g. cardiovascular disease, cancer). Randomization was conducted blind by a statistician independent to the research team. Eligible participants were block randomized (using a computer-generated random-number sequence). Following a preliminary run-in period (2 weeks), with no alcohol consumption, subjects consumed either red wine (240 mL) (Jacob’s Creek Shiraz Cabernet, South Eastern Australia; ABV 13.5% vol.) or vodka (80 mL) (Smirnoff vodka; ABV 37.5% vol.) for two weeks. This amount is equivalent to 24 g ethanol/day (3). After a 14-day washout period, subjects drank the alternate alcoholic beverage for a further 14 days (Figure 1). No other alcoholic beverages were consumed during the study period. Before the study began, participants were subjected to a full clinical assessment; weight, height and blood pressure measurement. Participants were asked to avoid changing their levels of physical activity or dietary patterns during the study period. Participants were also advised to avoid mixing the vodka intervention with fruit juice. This study was approved by the Faculty of Medicine Research Ethics Committee at Queen’s University Belfast, and all participants gave written informed consent.

**Blood sampling**

Fasting blood samples were collected before and after each treatment period in EDTA tubes and centrifuged at 4°C and 1590 g for 10 min for separation of serum and plasma (Sigma cooling centrifuge 4K15C; Sigma Laborzentrifugen GmbH, Osterode am Harz, Germany). Serum and plasma samples were stored at −80°C pending analysis.

**Laboratory analysis**

A total of 13 biomarkers were measured. Biomarkers measured in serum were CRP, interleukin-6 (IL-6), IL-18, intracellular adhesion molecule-1 (ICAM-1), vascular cell adhesion molecule-1 (VCAM-1), leptin, apolipoprotein A1 (APO A1) and apolipoprotein B (APO B). IL-6, IL-18, VCAM-1 and leptin were assayed using ELISA kits (R&D Systems, Abingdon, UK). ICAM-1 was also assayed using ELISA kits (Thermo Fisher, Swindon, UK). APO A1, APO B and CRP levels were determined by Immunoturbidimetric assay (Architect c8000; Abott, UK).

Biomarkers measured in plasma were adiponectin, matrix metalloproteinase-9 (MMP-9), tissue inhibitor of metalloproteinase 1 (TIMP-1), caspase-1 (CASP-1) and cystatin C. CASP-1 and adiponectin were assayed using ELISA kits (R&D Systems, Abingdon, UK). MMP-9 was assayed utilizing Enzyme immunoassay kits (Fuji Chemical Industries Co., Tokyo, Japan). TIMP-1 levels were determined by Chemiluminescent microparticle immunoassay (Architect i2000; Abbott, UK). Cystatin C concentrations were determined by Immunoturbidimetric assay (Architect c8000; Abott, UK). All intra and inter-assay coefficients of variation (CVs) were less than 7% and 17% respectively.

**Statistical analysis**

The final analysis only included study subjects who completed the study. The Hills & Armitage test was initially
Table 1. Baseline characteristics of study participants by intervention, during first treatment period.

<table>
<thead>
<tr>
<th>Intervention group (during first intervention period)</th>
<th>Vodka</th>
<th>Red wine</th>
</tr>
</thead>
<tbody>
<tr>
<td>n</td>
<td>41</td>
<td>36</td>
</tr>
<tr>
<td>Age (y)</td>
<td>39.9 (10.7)</td>
<td>47.7 (11.6)</td>
</tr>
<tr>
<td>BMI (kg/m²)</td>
<td>25.4 (4.3)</td>
<td>25.3 (1.7)</td>
</tr>
<tr>
<td>Systolic BP (mmHg)</td>
<td>124.8 (11.0)</td>
<td>128.1 (14.8)</td>
</tr>
<tr>
<td>Diastolic BP (mm Hg)</td>
<td>76.8 (7.9)</td>
<td>81.5 (12.0)</td>
</tr>
<tr>
<td>Usual alcohol consumption (units/week)</td>
<td>12.2 (14.9)</td>
<td>11.5 (8.9)</td>
</tr>
<tr>
<td>Smoking</td>
<td>5%</td>
<td>17%</td>
</tr>
<tr>
<td>CRP (mg/L)</td>
<td>0.61 (0.29, 1.35)</td>
<td>0.64 (0.44, 1.09)</td>
</tr>
<tr>
<td>IL-6 (pg/mL)</td>
<td>1.24 (0.72, 1.99)</td>
<td>1.29 (0.86, 1.75)</td>
</tr>
<tr>
<td>IL-18 (pg/mL)</td>
<td>273 (233, 377)</td>
<td>270 (211, 378)</td>
</tr>
<tr>
<td>Adiponectin (ng/mL)</td>
<td>5051 (3132, 7271)</td>
<td>6132 (4657, 8128)</td>
</tr>
<tr>
<td>Leptin (pg/mL)</td>
<td>4825 (2861, 8177)</td>
<td>5353 (4306, 6855)</td>
</tr>
<tr>
<td>VCAM-1 (ng/mL)</td>
<td>626 (525, 737)</td>
<td>628 (498, 795)</td>
</tr>
<tr>
<td>CASP-1 (pmol/L)</td>
<td>50.4 (37.2, 61.5)</td>
<td>39.7 (30.2, 56.6)</td>
</tr>
<tr>
<td>MMP-9 (mg/L)</td>
<td>122 (72, 153)</td>
<td>111 (70, 166)</td>
</tr>
<tr>
<td>TIMP-1 (ng/mL)</td>
<td>95 (79, 109)</td>
<td>99 (83, 116)</td>
</tr>
<tr>
<td>APO A1 (g/L)</td>
<td>1.32 (0.14)</td>
<td>1.37 (0.19)</td>
</tr>
<tr>
<td>APO B (g/L)</td>
<td>0.94 (0.24)</td>
<td>0.92 (0.22)</td>
</tr>
<tr>
<td>Cystatin C (mg/L)</td>
<td>0.74 (0.10)</td>
<td>0.76 (0.12)</td>
</tr>
<tr>
<td>ICAM-1 (ng/mL)</td>
<td>214 (38)</td>
<td>191 (45)</td>
</tr>
</tbody>
</table>

Data presented as mean (SD, geometric mean (25th, 75th percentile) or %. *Based on n = 76.

exploited for doing analysis (15). Given the absence of significant period or carry-over effects, paired samples t-tests were conducted for comparison of the intervention groups, as they provided a simpler presentation of results. In light of the multiple tests of significance performed with no prior hypotheses, the 1% significance level was used in all analyses. All statistical analyses were done using STATA release 14.0 (StataCorp, College Station, TX, USA) and SPSS version 22 (IBM Corp, Armonk, NY, USA).

Results

Of the 85 recruited study subjects, 77 subjects completed the entire study protocol. Table 1 shows the baseline characteristics. Participants randomized to receive red wine initially were older than those randomized to receive vodka, and there were more smokers initially randomized to red wine than to vodka.

Table 2 shows the changes in inflammatory markers, presented as either geometric mean ratio (post-intervention: pre-intervention) or difference in arithmetic means (post intervention – pre-intervention). Figure 2 presents the significant changes in the measured biomarkers. No significant changes were seen in the serum/plasma concentrations of CRP, IL-6, IL-18, VCAM-1, CASP-1, MMP-9, TIMP-1, APO B, Cystatin C or ICAM-1 following 2-week interventions with either vodka or red wine. Furthermore, no significant difference was seen between the vodka and red wine interventions for these markers. Although no significant increase in plasma adiponectin levels was observed following 14-day consumption of vodka [GM ratio (95% CI) 1.09 (1.02-1.17), p = 0.013] nor red wine intervention [GM ratio (95% CI) 0.96 (0.91-1.03), p = 0.24], comparison of change in adiponectin levels following the two interventions demonstrated a significant difference (p adjusted for period = 0.009). There were significant increases in serum leptin levels during both interventions [GM ratio (95% CI) vodka: 1.11 (1.04-1.17), p < 0.001; red wine: 1.12 (1.05-1.19), p < 0.001]; this increase did not differ between the interventions (p adjusted for period = 0.77). APO A1 levels were significantly increased following vodka intervention [mean difference (95% CI): 0.07 (0.05-0.09), p < 0.001], however no significant change was identified following red wine intervention [mean difference (95% CI) 0.03 (-0.02-0.07), p = 0.22], and the between-intervention difference was not significant (p = 0.11).

Discussion

This two-period crossover trial demonstrated a 2-week intervention with moderate alcohol consumption (red wine or vodka) was associated with a significant increase in leptin levels. Results also showed that a 2-week vodka period, but not red wine period, significantly raised APO A1 levels. A significant difference between the interventions was only noted for adiponectin, although no within group changes were observed for either red wine or vodka.

Adiponectin acts as an insulin-sensitizing adipocytokine, shown to have an inverse relationship with development of coronary heart disease (16). The protective effects are mediated by anti-atherogenic and anti-inflammatory mechanisms (16). This study did not show any significant increase in plasma adiponectin following either vodka or red wine interventions, yet there was a significant difference between these interventions, with numeric differences suggesting an increase following vodka and decrease following red wine. In contrast, a study of 34 healthy men, who were randomized to receive either 450 mL of red wine (40 g alcohol) or 450 mL of de-alcoholized red wine across a 4-week period, found that adiponectin levels were significantly increased following consumption of red wine when compared to de-alcoholized red wine (17). These inconsistent results may be attributed to the differences in alcohol amounts consumed in the latter study and the current study (40 versus 24 g, respectively). On the other hand, Imhof et al. (18) showed a significant increase in adiponectin levels among women, but not men, after consuming red wine in a randomized controlled crossover trial comparing the effect of 21-day consumption of ethanol, red wine, and beer, equivalent to 20 g ethanol/day for females, and 30 g/day for males. Later, the cross-sectional study conducted by Nishise et al. (19) in a Japanese population demonstrated a significantly inverse association between moderate alcohol intake (120-239 g/week) and adiponectin levels. Although only a cross-sectional study, this contradicts the results of studies conducted among European population and highlights the potential effect of ethnicity on adiponectin levels following alcohol consumption.

There are also conflicting results from the literature in relation to leptin and alcohol consumption. Leptin is a cytokine-type peptide hormone that is predominantly synthesized by adipocytes. It is best known for its involvement in energy homeostasis, including regulation of neuroendocrine...
function, feeding behavior and energy expenditure (20). There is evidence that leptin acts as a pro-inflammatory hormone, and defective or reduced leptin signaling can help to protect against atherosclerosis via anti-inflammatory mechanisms (20). It is possible that different types of alcohol may affect leptin levels differently, yet the current study demonstrated a significant increase in leptin levels following both alcohol interventions. Likewise, Djurovic et al. (21) conducted a randomized crossover trial of 87 healthy individuals who received either a 3-week red wine intervention or no alcohol, where a significant increase in leptin levels was shown after the red wine intervention compared to no alcohol. When split by gender, the relationship remained significant for women, but not for men. In contrast, Beulens et al. (22) measured changes in leptin after consumption of beer, nonalcoholic beer and gin in 33 men at high risk of CVD and reported that there was no evidence for significant differences in leptin levels across the three interventions. Due to the contradictory evidence currently reported concerning alcohol’s effect on leptin levels, there is a requirement for future research in the area to define the exact relationship and determine the mechanisms by which alcohol may exert its protective effects.

APO A1 and APO B have been reported to be early predictors of atherosclerotic diseases (23). APO A1 is known for its protective effects against atherosclerosis through mediating reverse cholesterol transport, whereas APO B has atherogenic effects (23, 24). The current study showed a significant increase in APO A1 levels following vodka, but not red wine intervention. APO B levels were not significantly raised following either intervention. An intervention study in 51 postmenopausal women by Baer et al. (23) showed similar results with regards to APO A1, which was significantly raised by 28-day alcohol consumption (30 g/day), yet APO B levels exhibited a significant decrease.

Population cohort studies have reported that inflammatory mediators such as IL-6 and CRP are positively associated with development and progression of atherosclerosis (25). This study did not demonstrate a significant change in IL-6, IL-18 or CRP levels following red wine or vodka intervention; these findings are supported by a number of studies across alcohol types (26–29). On the contrary, Joosten et al. (13) conducted a randomized controlled 28-day vodka (30 g/day) intervention study in 24 healthy males and showed a significant increase in APO A1 levels following vodka, but not red wine intervention. APO B levels were not significantly raised following either intervention. An intervention study

### Table 2. Effect of 14-day vodka or red wine intervention on biomarkers in 77 healthy adult men who completed the study.

<table>
<thead>
<tr>
<th>Study</th>
<th>Vodka intervention</th>
<th>Red wine intervention</th>
<th>Vodka versus Red Wine</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Mean difference</td>
<td>Mean difference</td>
<td>Mean difference</td>
</tr>
<tr>
<td></td>
<td>(95% CI)</td>
<td>(95% CI)</td>
<td>(95% CI)</td>
</tr>
<tr>
<td>CRP (mg/L)</td>
<td>0.70 0.69 0.99 (0.85,1.15)</td>
<td>0.68 0.78 1.14 (0.92,1.42)</td>
<td>0.21</td>
</tr>
<tr>
<td>IL-6 (pg/mL)</td>
<td>1.38 1.55 1.12 (0.95,1.33)</td>
<td>1.35 1.43 1.06 (0.88,1.28)</td>
<td>0.53</td>
</tr>
<tr>
<td>IL-18 (pg/mL)</td>
<td>282 277 0.98 (0.94,1.03)</td>
<td>281 278 0.99 (0.93,1.05)</td>
<td>0.71</td>
</tr>
<tr>
<td>Adiponectin (ng/mL)</td>
<td>5008 5478 1.09 (1.02,1.17)</td>
<td>5586 5386 0.96 (0.91,1.03)</td>
<td>0.24</td>
</tr>
<tr>
<td>Leptin (pg/mL)</td>
<td>5019 5547 1.11 (1.04,1.17)</td>
<td>&lt;0.001*</td>
<td>4803 5374 1.12 (1.05,1.19)</td>
</tr>
<tr>
<td>TIMP-1 (ng/mL)</td>
<td>198 219 0.94 0.98 (0.94,1.02)</td>
<td>0.27</td>
<td>96 93 0.97 (0.93,1.01)</td>
</tr>
</tbody>
</table>

*GM: geometric mean.

**: GM Ratio: ratio of geometric means (post/pre)

*: CI: confidence interval. Results displayed as GM and GM ratio for logarithmically-transformed variables and mean and arithmetic difference for normally distributed variables.

**: Based on n = 76.

*: p ≤ 0.01.

Figure 2. Changes in the measured biomarkers following the two treatment periods.
significant decrease in IL-18 levels. Furthermore, Vázquez-Agell et al. (8) reported significant reductions in IL-6 and CRP levels, following a 28-day sparkling wine intervention. In 2018, a cross-sectional study by Mangnus et al. (30) supported these findings, and revealed a significant J-shape relationship between CRP levels and alcohol consumption.

Secretion of endothelial adhesion molecules into the plasma acts as a sign of atherogenesis and endothelial dysfunction (31). Our results did not show any significant changes in VCAM-1 nor ICAM-1 levels following either vodka or red wine interventions. In contrast, an intervention study by Estruch et al. (32) has demonstrated reductions in ICAM-1 and VCAM-1 levels following 28-day red wine (33 g alcohol/day). This inconsistency in results may be linked to the difference in amount of alcohol consumed in our study and the latter study (24 versus 33 g, respectively). Furthermore, moderate alcohol consumption was found to be inversely associated with serum levels and suppresses endothelial expression of adhesion molecules (8, 32, 33). Observational studies have shown a significant J-shape relationship between alcohol consumption and ICAM-1, as well as E-selectin, whereas a U-shape curve was detected for VCAM-1 (31).

Changes in inflammatory molecules by alcohol could be attributed to alterations in gene expression (26). The alcohol consumed in the current study may have modulated the gene expression of the inflammatory and vascular health-related biomarkers examined. Our study showed that the higher polyphenol content of red wine did not show a more protective effect against CVD relative to vodka. This is consistent with previous research findings that suggested that red wine contains subtherapeutic concentrations of polyphenols (12). Longer and larger prospective studies are needed to inform alcohol interventions for prevention/management of CVD.

**Strengths and limitations**

This study was a randomized crossover study, which is a robust design, aiming to determine the effect of two different alcoholic beverages consumed in moderation, on a range of inflammatory and vascular-related biomarkers. Such an approach enhances the largely epidemiological literature relating to alcohol, alcohol type and vascular health outcomes. One limitation in this study is the relatively short duration of the wine/vodka intervention to compare the effect of the two different alcoholic beverages on inflammatory biomarkers. Given the variations in polyphenol content between red wine products, our study findings are specific to the particular red wine brand used in this study (i.e. Shiraz-Cabernet). The participants of our study were advised to maintain their normal diet throughout the trial period to avoid confounding by a change in diet; however, the diet of the subjects was not strictly regulated or monitored throughout the trial period. Researchers encouraged compliance with the intervention, but there was no formal measurement of compliance, which was self-reported by participants. The weight/BMI of the volunteers was recorded at baseline but was not re-measured post-intervention period, and we have not determined whether baseline BMI could have been associated with the influence of alcohol on inflammation. Furthermore, all individuals in this study were healthy volunteers without comorbidity and therefore, had low baseline risks. Our results, therefore, may not be representative of those who are most likely to benefit from the protective effects of alcohol.

**Conclusions**

Moderate consumption of either red wine or vodka had significant effects on leptin and APO A1. No significant differences in any other inflammatory and vascular biomarkers included in the study were detected. Whilst leptin concentrations showed a significant increase following both interventions, APO A1 exhibited a significant increase after vodka only. A statistically significant difference between interventions was only observed for adiponectin, although within-group changes were not statistically significant. Further research with large cohorts is required to validate these findings in order to best develop and guide cardiologists on alcohol preventive measures against CVD. Prospective research will also assess the impact of longer-term alcohol use on inflammatory and vascular health biomarkers related to CVD risk.

**Acknowledgments**

The authors would like to thank the Australian Wine Research Institute (Professor Terry), and the Ulster Vintners Association. The authors also thank Macrovector/Freepik for designing the heart diagram included in the graphical abstract.

**Author contributions**

ISY, PCS and AE designed the original study and were responsible for study conduct. CCP was study statistician and conducted the statistical analysis. SB’s laboratory conducted the biomarker analysis. MCM and JJVW conceived and directed the current analysis. AW, SE, NMa and KD contributed to the current analysis, literature review and paper draft. All authors approved the final manuscript.

**Disclosure statement**

The authors declare no conflict of interest.

**Funding**

This study was funded by The Partridge Foundation.

**References**


based cohort study using linked health records. BMJ. 2017; 356. doi:10.1136/bmj.j909.


